[
  {
    "ts": null,
    "headline": "GLP-1 questions emerge for 2025",
    "summary": "The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.",
    "url": "https://finnhub.io/api/news?id=10d16fd7419a29a826adae343cff42b8cce630ca6029cd6b54f4057e9d8f8745",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735681738,
      "headline": "GLP-1 questions emerge for 2025",
      "id": 132221988,
      "image": "https://s.yimg.com/ny/api/res/1.2/o.xKVkL_2cKm_990lun34w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2023-12/2d578f90-9d7d-11ee-bd6d-e9421ec244af",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.",
      "url": "https://finnhub.io/api/news?id=10d16fd7419a29a826adae343cff42b8cce630ca6029cd6b54f4057e9d8f8745"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE:NVO)’s share was trading at $85.73 as of Dec 30th. NVO’s trailing and forward P/E were 28.92 and 21.98 respectively according to Yahoo Finance. Novo Nordisk’s […]",
    "url": "https://finnhub.io/api/news?id=e96fa6f191b6b55ba39ac253c65b25e372610af0f58d41db52024e908bde36ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735664520,
      "headline": "Novo Nordisk A/S (NVO): A Bull Case Theory",
      "id": 132216395,
      "image": "https://media.zenfs.com/en/insidermonkey.com/9a940f431ed5c67ff01d3513aa691c9f",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE:NVO)’s share was trading at $85.73 as of Dec 30th. NVO’s trailing and forward P/E were 28.92 and 21.98 respectively according to Yahoo Finance. Novo Nordisk’s […]",
      "url": "https://finnhub.io/api/news?id=e96fa6f191b6b55ba39ac253c65b25e372610af0f58d41db52024e908bde36ea"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.",
    "summary": "It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.",
    "url": "https://finnhub.io/api/news?id=1d241cb1ecdcc9bff0c0cc72f2284de5f6a474d0c3114f9ee312c1093cacf838",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735656720,
      "headline": "Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.",
      "id": 132215459,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.",
      "url": "https://finnhub.io/api/news?id=1d241cb1ecdcc9bff0c0cc72f2284de5f6a474d0c3114f9ee312c1093cacf838"
    }
  },
  {
    "ts": null,
    "headline": "Akero Therapeutics: Where This Potential MASH Play Stands Currently",
    "summary": "Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.",
    "url": "https://finnhub.io/api/news?id=59f1490761432441566bcb1c76e1b8ca8e84060130f68c53918f19c2e06d32c5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735649392,
      "headline": "Akero Therapeutics: Where This Potential MASH Play Stands Currently",
      "id": 132216255,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.",
      "url": "https://finnhub.io/api/news?id=59f1490761432441566bcb1c76e1b8ca8e84060130f68c53918f19c2e06d32c5"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Low Volatility Stock to Buy Right Now?",
    "summary": "We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up […]",
    "url": "https://finnhub.io/api/news?id=85206a8b7c71e91d0c1d887f3c4cc53bd2d467d9671f123f7a09db131cd16404",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735644621,
      "headline": "Is Eli Lilly and Company (LLY) the Best Low Volatility Stock to Buy Right Now?",
      "id": 132223064,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall, with the S&P 500 up […]",
      "url": "https://finnhub.io/api/news?id=85206a8b7c71e91d0c1d887f3c4cc53bd2d467d9671f123f7a09db131cd16404"
    }
  },
  {
    "ts": null,
    "headline": "Dividends Done Right: 3 Stock Picks To Build Wealth The Smart Way",
    "summary": "The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks poised to benefit from major trends.",
    "url": "https://finnhub.io/api/news?id=0a3dfbbd8501e3809b117aff7e6fb6a6330cf745dd55436e96c68546607c865d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735630200,
      "headline": "Dividends Done Right: 3 Stock Picks To Build Wealth The Smart Way",
      "id": 132213404,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154515143/image_2154515143.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks poised to benefit from major trends.",
      "url": "https://finnhub.io/api/news?id=0a3dfbbd8501e3809b117aff7e6fb6a6330cf745dd55436e96c68546607c865d"
    }
  }
]